Can β-lactams be re-engineered to beat MRSA?
Open Access
- 1 January 2006
- journal article
- review article
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 12 (s2) , 11-16
- https://doi.org/10.1111/j.1469-0691.2006.01403.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Surveillance and epidemiology of MRSA bacteraemia in the UKJournal of Antimicrobial Chemotherapy, 2005
- MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistanceEmerging Therapeutic Targets, 2004
- Methicillin-resistantStaphylococcus aureusin Europe, 1999–2002Emerging Infectious Diseases, 2004
- In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British IslesInternational Journal of Antimicrobial Agents, 2003
- Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS)Journal of Antimicrobial Chemotherapy, 2001
- A New Class of Genetic Element, Staphylococcus Cassette Chromosome mec , Encodes Methicillin Resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2000
- Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals: Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses AssociationJournal of Hospital Infection, 1998
- The Progressive Intercontinental Spread of Methicillin-Resistant Staphylococcus aureusClinical Infectious Diseases, 1997
- Molecular aspects of methicillin resistance in Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 1994
- "Celbenin" - resistant StaphylococciBMJ, 1961